Natco pharma launches epilepsy drug Brivaracetam in India
NATCO's BRECITA tablets will be available in two strengths of 50 mg and 100 mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced the launch of Brivaracetam tablets under brand BRECITA in India.
Brivaracetam is indicated towards treatment of epilepsy.
Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact.
NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.
Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Next Story
